Effects of tGLP-1 on feeding behaviour and neurohypophysial function under chronic osmotic stimulation

Physiology and Behavior

Volumn 78, Issue 1, 2003, Pages 73-79

  Bojanowska, Ewa ^a   Stempniak, Bozena ^a  

^a MEDICAL UNIVERSITY OF LODZ   (Poland)

Author keywords

Drinking behaviour; Feeding behaviour; Osmotic stimulation; Oxytocin; Vasopressin

Indexed keywords

DRINKING WATER; GLUCAGON LIKE PEPTIDE 1 [7-36] AMIDE; NEUROHYPOPHYSIS HORMONE; OXYTOCIN; SODIUM CHLORIDE; VASOPRESSIN;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRINKING BEHAVIOR; DRUG EFFECT; ELECTROLYTE BALANCE; FEEDING BEHAVIOR; FLUID BALANCE; FLUID INTAKE; FOOD INTAKE; HEMATOCRIT; HORMONE RELEASE; MALE; NEUROHYPOPHYSIS; NONHUMAN; OSMOLALITY; OSMOTIC STRESS; OXYTOCIN BLOOD LEVEL; PRIORITY JOURNAL; RAT; SALT INTAKE; SALT LOADING; VASOPRESSIN BLOOD LEVEL; WEIGHT REDUCTION;

EID: 0037244463     PISSN: 00319384     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0031-9384(02)00891-0     Document Type: Article

References (45)

1. Spiegelman B.M., Flier J.S. Obesity and the regulation of energy balance. Cell. 104:2001;531-543.
2. Johnson R.F., Johnson A.K. The interaction of meal-related, rhythmic and homeostatic mechanisms and the generation of thirst and drinking. Braz. J. Med. Biol. Res. 30:1997;487-491.
3. De Castro J.M. The interactions of fluid and food intake in the spontaneous feeding and drinking patterns of rats. Physiol. Behav. 45:1989;861-870.
4. Jensen G.B., Collier G.H., Medvin M.B. A cost-benefit analysis of nocturnal feeding in the rat. Physiol. Behav. 31:1983;555-559.
5. Stricker W.M., Sved A.F. Thirst. Nutrition. 16:2000;821-826.
6. Schoorlemmer G.H.M., Johnson A.K., Thunhorst R.L. Effect of hyperosmotic solutions on salt excretion and thirst in rats. Am. J. Physiol. 278:2000;R917-R923.
7. Szczepańska-Sadowska E. Interaction of vasopressin and angiotensin II in central control of blood pressure and thirst. Regul. Pept. 66:1996;65-71.
8. Neumann I., Ludwig M., Engelmann M., Pittman Q.J., Landgraf R. Simultaneous microdialysis in blood and brain: oxytocin and vasopressin release in response to central and peripheral osmotic stimulation and suckling in the rat. Neuroendocrinology. 58:1993;637-645.
9. Ludwig M., Callahan M.F., Morris M. Effects of tetrodotoxin on osmotically stimulated central and peripheral vasopressin and oxytocin release. Neuroendocrinology. 62:1995;619-627.
10. Kadekaro M., Liu H., Terrell M.L., Gestl S., Bui V., Summy-Long J.Y. Role of NO on vasopressin and oxytocin release and blood pressure responses during osmotic stimulation in rats. Am. J. Physiol. 273:1997;R1024-R1030.
11. Share L. Control of vasopressin release: an old but continuing story. News Physiol. Sci. 11:1996;7-13.
12. Chowdrey H.S., Lightman S.L. Role of central amino acids and peptide-mediated pathways in neurohypophysial hormone release. Ann. N. Y. Acad. Sci. 689:1993;183-193.
13. Gehlert D.R. Role of hypothalamic neuropeptide Y in feeding and obesity. Neuropeptides. 33:1999;329-338.
14. Crawley J.N. The role of galanin in feeding behavior. Neuropeptides. 33:1999;369-375.
15. Landry M., Roche D., Calas A. Short-term effects of centrally administered galanin on the hyperosmotically stimulated expression of vasopressin in the rat hypothalamus. Neuroendocrinology. 61:1995;393-404.
16. Ritter R.C., Covasa M., Matson C.A. Cholecystokinin: proofs and prospects for involvement in control of food intake and body weight. Neuropeptides. 33:1999;387-399.
17. Nauck M.A., Holst J.J., Willms B., Schmiegel W. Glucagon-like peptide 1 (GLP-1) as a new therapeutic approach for type 2-diabetes. Exp. Clin. Endocrinol. Diabetes. 105:1997;187-195.
18. Gutzwiller J.P., Göke B., Drewe J., Hildebrand P., Ketterer S., Handschin D.et al. Glucagon-like peptide-1: a potent regulator of food intake in humans. Gut. 44:1999;81-86.
19. Gutzwiller J.P., Drewe J., Göke B., Schmidt H., Rohrer B., Lareida J.et al. Glucagon-like peptide-1 promotes satiety and reduces food intake in patients with diabetes mellitus type 2. Am. J. Physiol. 276:1999;R1541-R1544.
20. Toft-Nielsen M.B., Madsbad S., Holst J.J. Continuous subcutaneous infusion of glucagon-like peptide-1 lowers plasma glucose and reduces appetite in type 2 diabetic patients. Diabetes Care. 22:1999;1137-1143.
21. Flint A., Raben A., Ersbøll A.K., Holst J.J., Astrup A. The effect of physiological levels of glucagon-like peptide-1 on appetite, gastric emptying, energy and substrate metabolism in obesity. Int. J. Obes. 25:2001;781-792.
22. Navarro M., de Fonseca F.R., Alvarez E., Chowen J.A., Zueco J.A., Gomez R.et al. Colocalization of glucagon-like peptide-1 (GLP-1) receptors, glucose transporter GLUT-2, and glucokinase mRNAs in rat hypothalamic cells: evidence for a role of GLP-1 receptor agonists as an inhibitory signal for food and water intake. J. Neurochem. 67:1996;1982-1991.
23. Tang-Christensen M., Larsen P.J., Göke R., Fink-Jensen A.F., Jessop D.S., Møller M.et al. Central administration of GLP-1-(7-36) amide inhibits food and water intake in rats. Am. J. Physiol. 271:1996;R848-R856.
24. Turton M.D., O'Shea D., Gunn I., Beak S.A., Edwards C.M.B., Meeran K.et al. A role for glucagon-like peptide-1 in the central regulation of feeding. Nature. 379:1996;69-72.
25. Furuse M., Matsumoto M., Okumura J., Sugahara K., Hasegawa S. Intracerebroventricular injection of mammalian and chicken glucagon-like peptide-1 inhibits food intake of the neonatal chick. Brain Res. 755:1997;167-169.
26. Wang T., Edwards G.L., Baile C.A. Glucagon-like peptide-1 (7-36) amide administered into the third cerebroventricle inhibits water intake in rats. Proc. Soc. Exp. Biol. Med. 219:1998;85-91.
27. Larsen P.J., Tang-Christensen M., Jessop D.S. Central administration of glucagon-like peptide-1 activates hypothalamic neuroendocrine neurons in the rat. Endocrinology. 138:1997;4445-4455.
28. Bojanowska E., Stempniak B. Effects of centrally or systemically injected glucagon-like peptide-1 (7-36) amide on release of neurohypophysial hormones and blood pressure in the rat. Regul. Peptides. 91:2000;75-81.
29. Bojanowska E., Stempniak B. Effects of glucagon-like peptide-1 (7-36) amide on neurohypophysial and cardiovascular functions under hypo- or normotensive hypovolaemia in the rat. J. Endocrinol. 172:2002;303-310.
30. Naimi N., Rivest S., Racotta I., Richard D. Neuronal activation of the hypothalamic magnocellular system in response to oropharyngeal stimuli in the rat. J. Neuroendocrinol. 9:1997;329-340.
31. Burlet A.J., Jhanwar-Uniyal M., Chapleur-Chateau M., Burlet C.R., Leibowitz S.F. Effect of food deprivation and refeeding on the concentration of vasopressin and oxytocin in discrete hypothalamic sites. Pharmacol. Biochem. Behav. 43:1992;897-905.
32. Chaillou E., Baumont R., Tramu G., Tillet Y. Effect of feeding on Fos protein expression in sheep hypothalamus with special reference to the supraoptic and paraventricular nuclei: an immunohistochemical study. Eur. J. Neurosci. 12:2000;4515-4524.
33. Göke R., Larsen P.J., Mikkelsen J.D., Sheikh S.P. Distribution of GLP-1 binding sites in the rat brain: evidence that exendin-4 is a ligand of brain GLP-1 binding sites. Eur. J. Neurosci. 7:1995;2294-2300.
34. Merchenthaler I., Lane M., Shughrue P. Distribution of pre-pro-glucagon and glucagon-like peptide-1 receptor messenger RNAs in the rat central nervous system. J. Comp. Neurol. 403:1999;261-280.
35. Bojanowska E., Forsling M.L. The effects of melatonin on vasopressin secretion in vivo: interactions with acetylcholine and prostaglandins. Brain Res. Bull. 42:1997;457-461.
36. Meeran K., O'Shea D., Edwards M.B., Turton M.D., Heath M.M., Gunn I.et al. Repeated intracerebroventricular administration of glucagon-like peptide-1-(7-36) amide or exendin-(9-39) alters body weight in the rat. Endocrinology. 140:1999;244-250.
37. Davis H.R., Mullins D.E., Pines J.M., Hoos L.M., France C.F., Compton D.S.et al. Effect of chronic central administration of glucagon-like peptide-1 (7-36) amide on food consumption and body weight in normal and obese rats. Obes. Res. 6:1998;147-156.
38. Donahey J.C.K., van Dijk G., Woods S.C., Seeley R.J. Intraventricular GLP-1 reduces short-but not long-term food intake or body weight in lean and obese rats. Brain Res. 779:1998;75-83.
39. Van Dijk G., Thiele T.E. Glucagon-like peptide-1 (7-36) amide: a central regulator of satiety and interoceptive stress. Neuropeptides. 33:1999;406-414.
40. O'Keefe J.A., Crowley R.S., Hrivnak P., Kim N.B., Amico J.A. Effect of testosterone and its metabolites upon the level of vasopressin messenger ribonucleic acid in the hypothalamus of the hyperosmotically stimulated male rat. Neuroendocrinology. 61:1995;405-411.
41. Morita M., Kita Y., Notsu Y. Mechanism of AVP release and synthesis in chronic salt-loaded rats. J. Pharm. Pharmacol. 53:2001;1703-1709.
42. Tang-Christensen M., Vrang N., Larsen P.J. Glucagon-like peptide-1 (7-36) amide's central inhibition of feeding and peripheral inhibition of drinking are abolished by neonatal monosodium glutamate treatment. Diabetes. 47:1998;530-537.
43. Johnson A.K., Gross P.M. Sensory circumventricular organs and brain homeostatic pathways. FASEB J. 7:1993;678-686.
44. Näslund E., Bogefors J., Gryback P., Bjellerup P., Jacobsson H., Holst J.J.et al. GLP-1 inhibits gastric emptying of water but does not influence plasma vasopressin, sodium, or osmolality. Scand. J. Gastroenterol. 36:2001;156-162.
45. Näslund E., Bogefors J., Skogar S., Grybäck P., Jacobsson H., Holst J.J.et al. GLP-1 slows solid gastric emptying and inhibits insulin, glucagons, and PYY release in humans. Am. J. Physiol. 277:1999;R910-R916.